Chiles Research Institute/X
Apr 28, 2025, 17:07
Bernard Fox: Unifying cancer science and cedicine for impact at AACR 2025 and beyond
Bernard Fox, Co-Founder, President and CEO of UbiVac, shared a post on LinkedIn by Dominik Ruettinger, SVP, Global Head of Research and Early Development of Oncology at Bayer, adding:
“This perspective from a friend and colleague, Dr. Dominik Ruettinger, Bayer, really resonates with me as I am flying to Chicago to spend the next few days doing what I can to make a difference. Think this should be a goal for AACR2025 meeting and something we should focus on throughout the year and at AAI2025, ASCO2025, ESMO2025, SITC2025 and ASH2025 – ‘Unifying cancer science and medicine: a continuum of innovation for impact’. Let’s push harder to make more of a difference for patients with cancer and FinishCancer for good!”
Quoting Dominik Ruettinger’s post:
“This year’s annual meeting of the American Association for Cancer Research (AACR) is held in Chicago. It was a great pleasure to provide an update on our precision drug development strategy in Oncology R&D. Very much in line with this year’s motto of ‘Unifying cancer science and medicine: a continuum of innovation for impact’, it was enriching to exchange with industry peers, investors and academia. I am now looking forward to the main meeting at AACR25. Make sure to check out some key research updates that Bayer Pharmaceuticals and Vividion Therapeutics, Inc. will be presenting.”
More posts featuring Bernard Fox.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 28, 2025, 17:07
Apr 28, 2025, 16:35
Apr 28, 2025, 16:19